Literature DB >> 11956886

Hemolytic uremic syndrome: epidemiology, pathophysiology, and therapy.

Sharon P Andreoli1, Howard Trachtman, David W K Acheson, Richard L Siegler, Tom G Obrig.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11956886     DOI： 10.1007/s00467-001-0783-0

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


× No keyword cloud information.
  27 in total

1.  Rapid detection of Shiga toxin-producing Escherichia coli by optical immunoassay.

Authors:  Louise D Teel; Judy A Daly; Robert C Jerris; Diana Maul; Gregory Svanas; Alison D O'Brien; Choong H Park
Journal:  J Clin Microbiol       Date:  2007-08-01       Impact factor: 5.948

2.  Shiga-toxigenic Escherichia coli-inoculated neonatal piglets develop kidney lesions that are comparable to those in humans with hemolytic-uremic syndrome.

Authors:  J F Pohlenz; K R Winter; E A Dean-Nystrom
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

3.  Subtype-specific suppression of Shiga toxin 2 released from Escherichia coli upon exposure to protein synthesis inhibitors.

Authors:  Malene Gantzhorn Pedersen; Claus Hansen; Erik Riise; Søren Persson; Katharina E P Olsen
Journal:  J Clin Microbiol       Date:  2008-07-23       Impact factor: 5.948

4.  Hemolytic uremic syndrome in an infant following Bordetella pertussis infection.

Authors:  I Pela; D Seracini; A Caprioli; F Castelletti; A Giammanco
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

Review 5.  Glycosphingolipid functions.

Authors:  Clifford A Lingwood
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-07-01       Impact factor: 10.005

Review 6.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

7.  The hemorrhagic coli pilus (HCP) of Escherichia coli O157:H7 is an inducer of proinflammatory cytokine secretion in intestinal epithelial cells.

Authors:  Maria A Ledesma; Sara A Ochoa; Ariadnna Cruz; Luz M Rocha-Ramírez; Jaime Mas-Oliva; Carlos A Eslava; Jorge A Girón; Juan Xicohtencatl-Cortes
Journal:  PLoS One       Date:  2010-08-12       Impact factor: 3.240

Review 8.  Pathogenicity, host responses and implications for management of enterohemorrhagic Escherichia coli O157:H7 infection.

Authors:  Nathan K Ho; Aleah C Henry; Kathene Johnson-Henry; Philip M Sherman
Journal:  Can J Gastroenterol       Date:  2013       Impact factor: 3.522

9.  Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody.

Authors:  Kristin A D Sauter; Angela R Melton-Celsa; Kay Larkin; Megan L Troxell; Alison D O'Brien; Bruce E Magun
Journal:  Infect Immun       Date:  2008-08-11       Impact factor: 3.441

Review 10.  All blood, no stool: enterohemorrhagic Escherichia coli O157:H7 infection.

Authors:  Jang W Yoon; Carolyn J Hovde
Journal:  J Vet Sci       Date:  2008-09       Impact factor: 1.672
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.